Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Type 1 Diabetes at a Crossroads

Pathway to Artificial Pancreas Systems Revisited: Moving Downstream

  1. Aaron Kowalski⇑
  1. JDRF, New York, NY
  1. Corresponding author: Aaron Kowalski, akowalski{at}jdrf.org.
Diabetes Care 2015 Jun; 38(6): 1036-1043. https://doi.org/10.2337/dc15-0364
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    2009 AP road map. A target-product profile-based approach to envision iterative steps of increasing automation of insulin delivery initially toward a more physiological multihormone delivery eventually.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    For new technologies to succeed, they must demonstrate value to key stakeholders. An example/nonexhaustive list of areas of importance is shown.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Revised AP road map. AP system development can be condensed from six steps to three and has bifurcated into automated insulin delivery approaches utilizing solely insulin (AID) and multihormone approaches (MH), which may utilize insulin and glucagon, insulin and amylin, or insulin and other glucose-modulating agents.

Tables

  • Figures
  • Table 1

    AP road map in 2015: proof of concept of five of six steps of iteratively more sophisticated AP systems has been demonstrated in outpatient trials

    Step123456
    NameLGSPredictive LGS (PLGS)Hypoglycemia hyperglycemic minimizer (HHM)Hybrid closed loop (HCL)Fully automated insulin deliveryMultihormone (MH)
    SynonymsThreshold suspend (TS)Predictive low-glucose management system (PLGM)Treat-to-range system (TTR)Treat-to-target system (TTT)Fully closed loop (FCL)Insulin-glucagon system, bionic pancreas
    DescriptionInsulin shuts off upon crossing preset threshold such as 70 mg/dL and resumes after 2 hInsulin shuts off or is attenuated upon prediction of impending hypoglycemia and resumes delivery when hypoglycemia risk is goneSame as step 2 but with automatic insulin dosing to reduce hyperglycemia exposure. Does not target euglycemia, rather the minimization of time spent above a certain threshold, i.e., 180 mg/dLAlgorithm aims for euglycemic target, not range, but relies on mealtime insulin bolusFully automated insulin delivery with minimal human interactionFully automated multihormone approach; insulin plus glucagon, amylin, or other hormones/analogs
    2015 statusCommercialized globallyRegulatory approval outside U.S., commercial availability in AustraliaIn commercial developmentIn commercial developmentProof of conceptIn commercial development
    Example of supporting dataReduction in hypoglycemia, reduction in severe hypoglycemia, maintenance of A1C (29,43)Reduction in severe and moderate hypoglycemia (20,44)Reduction in time spent hyperglycemic and hypoglycemic and increased time in target range in outpatient settings (45)Reduction in time spent hyperglycemic and hypoglycemic and increased time in target range in outpatient settings (24,46)Reduction in hyperglycemia and hypoglycemia and increase in time in target in an inpatient settings (42,46)Reduction in hyperglycemia and hypoglycemia and increase time in target in outpatient setting (9)
PreviousNext
Back to top
Diabetes Care: 38 (6)

In this Issue

June 2015, 38(6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pathway to Artificial Pancreas Systems Revisited: Moving Downstream
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pathway to Artificial Pancreas Systems Revisited: Moving Downstream
Aaron Kowalski
Diabetes Care Jun 2015, 38 (6) 1036-1043; DOI: 10.2337/dc15-0364

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Pathway to Artificial Pancreas Systems Revisited: Moving Downstream
Aaron Kowalski
Diabetes Care Jun 2015, 38 (6) 1036-1043; DOI: 10.2337/dc15-0364
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Key Question: What is an AP?
    • Key Questions: Do We Need AP Systems? Is There an Unmet Need? Are Diabetes Outcomes Suboptimal Because Tools Are Lacking or Because of Lack of Compliance With Today’s Therapies?
    • Key Questions: Are AP Systems Technically Feasible Today? Can an AP System Replicate the Function of the Islet?
    • Key Question: Must AP Systems Use Glucagon?
    • Key Questions: Where Do We Go From Here? What AP Systems Will Reach the Clinic and When?
    • Key Question: Where Will the AP Field Head in the Next 10 Years?
    • Summary
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Type 1 Diabetes at a Crossroads!
  • Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
Show more Type 1 Diabetes at a Crossroads

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.